Former Virginia Gov. Glenn Youngkin is returning to the investment world as Red Cell Partners expands its effort to build a new generation of defense, cybersecurity and healthcare technology companies.

The McLean-based venture studio announced that Youngkin has joined the firm as a partner, chairman and board member. The position brings him back to private capital after four years as governor and a 25-year career at The Carlyle Group, where he rose to co-chief executive.

Youngkin is expected to help Red Cell strengthen relationships with investors, government agencies, major corporations and potential business partners. He told Axios that the role will occupy approximately one or two days each week.

The appointment is more than a return to dealmaking. It places Youngkin inside a firm built around one of the most consequential questions facing the United States: how to move promising technology into military use quickly enough to keep pace with increasingly capable competitors.

Red Cell argues that the traditional defense acquisition system is too concentrated, too slow and too difficult for many emerging companies to navigate.

The firm’s national-security strategy focuses on bringing smaller, more agile technology companies into the defense industrial base while helping them manage procurement rules, regulatory requirements, government relationships and the difficult transition from prototype to production.

Red Cell says the five largest defense contractors have accounted for roughly 30% to 36% of defense contract obligations in recent years. At the same time, the Pentagon has reported a significant decline in the number of small businesses participating in the defense industrial base over the past decade.

That creates an opening for firms capable of combining venture capital with operational expertise and an understanding of the federal market.

Founded in 2020 by entrepreneur Grant Verstandig, Red Cell operates as a venture studio rather than a conventional investment fund.

The company does not simply provide capital to existing startups. It identifies problems in national security, cybersecurity and healthcare, recruits leadership teams, develops technology and helps build companies from the ground up.

Verstandig previously founded Rally Health, a consumer healthcare technology company acquired by UnitedHealth Group in a transaction valued at approximately $4 billion. He later helped create several businesses now associated with Red Cell, including defense technology company Epirus and artificial intelligence platform Trase.

Red Cell’s portfolio includes companies working on autonomous systems, artificial intelligence, cybersecurity, energy infrastructure and defense supply-chain resilience.

Epirus develops high-power microwave systems intended to counter drones and other electronic threats. Hunted Labs focuses on securing the software supply chain. Vantive is developing technology to help defense organizations identify and respond to supply-chain risks. DeployX is another internally developed national-security company.

The firm says it prioritizes technologies that address mission-critical national needs, comply with federal requirements, have support from government and industry leaders and can meaningfully improve operational capabilities.

Its approach reflects a broader shift in defense investing. Venture firms are increasingly trying to finance companies that can deliver commercial-style development speed while still operating within the heavily regulated federal procurement system.

Red Cell’s national-security practice is led by Veronica Daigle, a former assistant secretary of defense for readiness who has also held senior roles at Boeing and within the federal government. The firm has described its priorities as industrial resilience, military readiness and force capability.

Youngkin’s background gives Red Cell an executive familiar with both institutional investment and government decision-making.

He joined Carlyle in 1995, when the firm was still relatively young, and helped oversee its growth into one of the world’s largest private investment companies. He has said Red Cell’s current trajectory reminds him of Carlyle’s earlier expansion.

As governor, Youngkin emphasized business recruitment, advanced manufacturing, data centers, pharmaceuticals, energy and defense-related investment. His administration was involved in major announcements from companies including Amazon, Eli Lilly and AstraZeneca.

That experience could be valuable to Red Cell companies seeking manufacturing sites, government approvals, workforce partnerships, corporate customers and access to public-sector decision-makers.

Youngkin said the firm is combining technical talent, industry expertise and private capital to build companies addressing problems that are important both commercially and to the country.

Red Cell is also expanding financially. Axios reported that the firm’s second investment fund has already exceeded the $91.2 million raised by its first. Red Cell also has approximately $150 million in a separate holding company used to incubate and develop businesses internally.

The appointment also strengthens an emerging defense technology axis inside Virginia.

Northern Virginia has the capital, federal agencies, defense headquarters, cybersecurity companies and policy infrastructure needed to launch national-security businesses.

Hampton Roads has the operational environment.

The region is home to the world’s largest naval base, major shipbuilding and repair operations, NATO’s Allied Command Transformation and thousands of defense contractors and military personnel. It offers emerging companies access to the customers, industrial facilities and real-world missions their technologies are intended to support.

As companies develop artificial intelligence, autonomous vessels, counter-drone systems, advanced manufacturing tools and supply-chain platforms, Hampton Roads can serve as the place where those technologies move from investment thesis to operational use.

The opportunity for Virginia is to connect Northern Virginia’s technology and capital ecosystem more deliberately with Hampton Roads’ maritime and military concentration.

Red Cell’s strategy is based on the belief that America cannot rely exclusively on its largest traditional contractors to develop every capability needed for future conflicts. The country also needs smaller companies that can move quickly, challenge established methods and bring commercially developed technology into the defense market.

Youngkin now returns to the private sector at the center of that effort.

His immediate role may be focused on investors, partnerships and company growth. But the larger work will be helping Red Cell turn private capital and emerging technology into capabilities that the American military can actually buy, deploy and scale.

Forward this to one person who needs to understand Hampton Roads.

Subscribe @ theledgerstar.com

The Ledger Star is an independent digital publication covering the people, decisions, investments, and ideas shaping the future of Hampton Roads. It focuses on what matters most to the region's business, civic, and community leaders, providing context and analysis rather than chasing every headline.